787 Stock Overview
Operates as a contract research organization worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 787 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Selvita S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł11.06 |
| 52 Week High | zł16.46 |
| 52 Week Low | zł10.76 |
| Beta | 0.026 |
| 1 Month Change | -5.47% |
| 3 Month Change | -25.87% |
| 1 Year Change | -18.20% |
| 3 Year Change | -36.44% |
| 5 Year Change | n/a |
| Change since IPO | -10.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 787 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -9.3% | -0.7% | -1.4% |
| 1Y | -18.2% | -3.9% | 8.0% |
Return vs Industry: 787 underperformed the German Life Sciences industry which returned -3.9% over the past year.
Return vs Market: 787 underperformed the German Market which returned 8.1% over the past year.
Price Volatility
| 787 volatility | |
|---|---|
| 787 Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 787 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 787's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 387 | Boguslaw Sieczkowski | selvita.com |
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, autoimmune/immunology, neurology, respiratory, and other.
Selvita S.A. Fundamentals Summary
| 787 fundamental statistics | |
|---|---|
| Market cap | €218.96m |
| Earnings (TTM) | €12.68m |
| Revenue (TTM) | €78.37m |
17.3x
P/E Ratio2.8x
P/S RatioIs 787 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 787 income statement (TTM) | |
|---|---|
| Revenue | zł334.42m |
| Cost of Revenue | zł71.47m |
| Gross Profit | zł262.96m |
| Other Expenses | zł208.86m |
| Earnings | zł54.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.95 |
| Gross Margin | 78.63% |
| Net Profit Margin | 16.18% |
| Debt/Equity Ratio | 37.9% |
How did 787 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 12:53 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Selvita S.A. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Sylwia Jaskiewicz | Dom Maklerski Banku Ochrony Srodowiska S.A. |